![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Favorable Preclinical Profile of IDX21437, a Novel Uridine Nucleotide Prodrug, for Use in a Direct-Acting Antiviral (DAA) Regimen for HCV
|
|
|
Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C - (04/07/14)
Reported by Jules Levin
EASL April 9-13, 2014, London, UK
K Gupta1, M Seifer1, I Serra1, H Rashidzadeh1, S Luo1, M La Colla1, X-R Pan-Zhou1, C Chapron1, B Hernandez-Santiago1, C Parsy2, F-R Alexandre2, B Mayes1, S Bhadresa1, A Moussa1, R Rush1
1 Idenix Pharmaceuticals, Inc., Cambridge, MA, USA; 2Idenix Medicinal Chemistry Research Laboratory, Montpellier, France.
![EASL1.gif](../images/041714/041614-6/EASL1.gif)
![EASL2.gif](../images/041714/041614-6/EASL2.gif)
![EASL3.gif](../images/041714/041614-6/EASL3.gif)
![EASL4.gif](../images/041714/041614-6/EASL4.gif)
![EASL5.gif](../images/041714/041614-6/EASL5.gif)
![EASL6.gif](../images/041714/041614-6/EASL6.gif)
![EASL7.gif](../images/041714/041614-6/EASL7.gif)
![EASL8.gif](../images/041714/041614-6/EASL8.gif)
![EASL9.gif](../images/041714/041614-6/EASL9.gif)
![EASL10.gif](../images/041714/041614-6/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|